Sheaff Brock Investment Advisors LLC Acquires 15,500 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL)

Sheaff Brock Investment Advisors LLC lifted its holdings in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) by 71.3% during the 4th quarter, Holdings Channel reports. The firm owned 37,250 shares of the biotechnology company’s stock after purchasing an additional 15,500 shares during the period. Sheaff Brock Investment Advisors LLC’s holdings in Anavex Life Sciences were worth $347,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Independent Advisor Alliance grew its stake in Anavex Life Sciences by 10.4% during the fourth quarter. Independent Advisor Alliance now owns 47,644 shares of the biotechnology company’s stock worth $444,000 after buying an additional 4,500 shares in the last quarter. Hayek Kallen Investment Management acquired a new stake in shares of Anavex Life Sciences during the 4th quarter worth approximately $99,000. BNP Paribas Financial Markets increased its stake in Anavex Life Sciences by 34.2% in the fourth quarter. BNP Paribas Financial Markets now owns 111,032 shares of the biotechnology company’s stock valued at $1,034,000 after acquiring an additional 28,297 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Anavex Life Sciences by 2.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 622,310 shares of the biotechnology company’s stock valued at $5,794,000 after purchasing an additional 17,499 shares in the last quarter. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Anavex Life Sciences by 187.3% in the fourth quarter. Los Angeles Capital Management LLC now owns 58,087 shares of the biotechnology company’s stock worth $541,000 after acquiring an additional 37,867 shares during the last quarter. 31.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a research report on Friday, May 10th.

Anavex Life Sciences Stock Performance

Shares of AVXL stock traded up $0.05 during mid-day trading on Friday, hitting $4.55. The company’s stock had a trading volume of 942,737 shares, compared to its average volume of 1,171,921. The company has a market cap of $385.12 million, a PE ratio of -9.10 and a beta of 0.66. The company’s fifty day simple moving average is $4.34 and its 200-day simple moving average is $5.82. Anavex Life Sciences Corp. has a 52 week low of $3.25 and a 52 week high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). During the same quarter in the previous year, the business posted ($0.17) earnings per share. On average, equities analysts anticipate that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Christopher U. Missling sold 73,380 shares of the stock in a transaction that occurred on Thursday, March 28th. The shares were sold at an average price of $5.11, for a total transaction of $374,971.80. Following the completion of the transaction, the chief executive officer now directly owns 1,250,210 shares of the company’s stock, valued at approximately $6,388,573.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 11.00% of the company’s stock.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.